Shields Health Solutions

shieldshealthsolutions.com

One of the fastest growing companies in America, Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and growth. The company provides the fastest, lowest risk model for Hospital leaders to create and grow a hospital-owned specialty pharmacy business, whether starting from scratch or adding specialty capabilities to a hospital’s existing pharmacy programs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT, MEDICAL

EMULATE PUBLISHES LANDMARK STUDY VALIDATING ORGAN-ON-A-CHIP TECHNOLOGY FOR PREDICTIVE TOXICOLOGY IN PRECLINICAL DEVELOPMENT

Emulate, Inc. | December 07, 2022

news image

Emulate, Inc., the leading provider of next-generation in vitro models announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which...

Read More

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

news image

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More

BETTERLIFE SCALES UP MANUFACTURING OF AP-003 (INTERFERON ALPHA 2B) TO PREPARE FOR CLINICAL TRIALS

BetterLife Pharma Inc. | September 17, 2020

news image

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has entered into an agreement with List Biological Laboratories, Inc. (“List Labs”) for the manufacture of its proprietary interferon alpha 2b for the treatment of COVID-19. "Following our recent merger, we are proud to be continuing the development of Altum Pharmaceutical’s proprietary interferon alpha 2b inh...

Read More

PHANES THERAPEUTICS REVEALS A NEW BISPECIFIC ANTIBODY TECHNOLOGY PLATFORM AT BIO DIGITAL 2020

Phanes Therapeutics | June 16, 2020

news image

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Read More
news image

INDUSTRIAL IMPACT, MEDICAL

EMULATE PUBLISHES LANDMARK STUDY VALIDATING ORGAN-ON-A-CHIP TECHNOLOGY FOR PREDICTIVE TOXICOLOGY IN PRECLINICAL DEVELOPMENT

Emulate, Inc. | December 07, 2022

Emulate, Inc., the leading provider of next-generation in vitro models announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which...

Read More
news image

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More
news image

BETTERLIFE SCALES UP MANUFACTURING OF AP-003 (INTERFERON ALPHA 2B) TO PREPARE FOR CLINICAL TRIALS

BetterLife Pharma Inc. | September 17, 2020

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has entered into an agreement with List Biological Laboratories, Inc. (“List Labs”) for the manufacture of its proprietary interferon alpha 2b for the treatment of COVID-19. "Following our recent merger, we are proud to be continuing the development of Altum Pharmaceutical’s proprietary interferon alpha 2b inh...

Read More
news image

PHANES THERAPEUTICS REVEALS A NEW BISPECIFIC ANTIBODY TECHNOLOGY PLATFORM AT BIO DIGITAL 2020

Phanes Therapeutics | June 16, 2020

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Read More

Resources

resource image

CELL AND GENE THERAPY

Lipid Nanoparticle and Liposome

Whitepaper

resource image

CELL AND GENE THERAPY

BCIT Biotechnology

Video

resource image

MEDICAL

THE RNA PLATFORM

Whitepaper

resource image

CELL AND GENE THERAPY

Lipid Nanoparticle and Liposome

Whitepaper

resource image

CELL AND GENE THERAPY

BCIT Biotechnology

Video

resource image

MEDICAL

THE RNA PLATFORM

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us